| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Schwartz Jonathan David | Chief Medical & Gene Therapy Officer | C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY | /s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz | 2025-05-22 | 0001726398 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RCKT | Common Stock | Sale | -$5.16K | -801 | -0.34% | $6.45 | 235K | May 20, 2025 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. |
| F2 | The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. |
Chief Medical & Gene Therapy Officer